Search research articles
Contact Us
Filters
Showing results (101-110 of 121) with videos related to
Page
of 13
Sort By:
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 14, 2025
Efficacy and safety of home-based transcranial direct current stimulation as adjunct treatment for cognitive improvement in major depressive disorder: A double-blind, randomized, multi-site clinical trial
C W Lee, K Park, J E Ahn, et al.
Blood
|
January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Blood
|
March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun, Pia Nierman, Ellen K Kendall, et al.
Blood Cancer Journal
|
August 29, 2025
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
Christine E Ryan, Inhye E Ahn, Aswin Sekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood
|
November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
Deyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood
|
January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Blood Advances
|
January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Inhye E Ahn, Danielle M Brander, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 121) with videos related to
Sort By:
Page
of 13
Blood Advances
|
May 23, 2023
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
Maissa Mhibik, Erika M Gaglione, David Eik, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
January 14, 2025
Efficacy and safety of home-based transcranial direct current stimulation as adjunct treatment for cognitive improvement in major depressive disorder: A double-blind, randomized, multi-site clinical trial
C W Lee, K Park, J E Ahn, et al.
Blood
|
January 5, 2017
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E Ahn, Chingiz Underbayev, Adam Albitar, et al.
Blood
|
March 24, 2020
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun, Pia Nierman, Ellen K Kendall, et al.
Blood Cancer Journal
|
August 29, 2025
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
Christine E Ryan, Inhye E Ahn, Aswin Sekar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2025
Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Blood
|
November 14, 2022
NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts
Deyi Zhang, Hailey M Harris, Jonathan Chen, et al.
Blood
|
January 8, 2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Sivasubramanian Baskar, Haiyong Peng, Erika M Gaglione, et al.
Blood Advances
|
January 1, 2024
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Inhye E Ahn, Danielle M Brander, Yue Ren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2024
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
Matthew S Davids, Christine E Ryan, Benjamin L Lampson, et al.
Page
of 13